First Trust Advisors
RNAC icon

First Trust Advisors’s Cartesian Therapeutics RNAC Stock Holding History

First Trust Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,288
Closed -$346K – 2473
2023
Q2 		$346K Buy
10,288
+102
+1% +$3.65K ﹤0.01% 2218
2023
Q1 		$425K Buy
10,186
+777
+8% +$36.5K ﹤0.01% 2173
2022
Q4 		$319K Sell
9,409
-633
-6% -$26.9K ﹤0.01% 2301
2022
Q3 		$494K Buy
+10,042
New +$552K ﹤0.01% 2211

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors's RNAC Position: Q3 2023 in Review

First Trust Advisors sold out of Cartesian Therapeutics (RNAC) in Q3 2023, closing a stake of 10,288 shares — an estimated $346K sold.

First Trust Advisors first reported a position in RNAC in Q3 2022 and held it in 4 quarters. The position peaked at $494K in Q3 2022. 87 funds tracked by Wall St. Rank hold RNAC as of Q3 2023.

  • First Trust Advisors reported no remaining Cartesian Therapeutics position as of Q3 2023 after selling out during the quarter.
  • First Trust Advisors sold 10,288 Cartesian Therapeutics shares in Q3 2023, an estimated $346K.
  • First Trust Advisors first reported a position in Cartesian Therapeutics in Q3 2022 and held it in 4 quarters.
  • First Trust Advisors's Cartesian Therapeutics position peaked at $494K in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.